All studies mention at least sporadic testing for BRAF V600E or MLH1 promoter hypermethylation in tumors showing MLH1/PMS2 loss, recognizing the significance of these markers in distinguishing sporadic from inherited MMR deficiency. The gene discussed is PMS2; the disease is mismatch repair cancer syndrome 1.